The β-Lactams Strike Back: Ceftazidime-Avibactam.
Citations
412 citations
Cites background or methods from "The β-Lactams Strike Back: Ceftazid..."
...ceftazidime-avibactam has been made available recently [Zasowski et al. 2015]....
[...]
...Despite the difficulties though, a new compound, ceftazidime-avibactam has been made available recently [Zasowski et al. 2015]....
[...]
271 citations
Cites background from "The β-Lactams Strike Back: Ceftazid..."
...However, relebactam cannot inhibit Class D OXA-48 like avibactam (Petty et al., 2018; Zhanel et al., 2018)....
[...]
...One in vitro study reported variable synergistic patterns among KPC and OXA-48 producers, while no synergism was observed for the NDM-producing strain (Poirel et al., 2016)....
[...]
...Some carbapenem-producing Enterobacteriaceae (CPE) are even susceptible to carbapenems themselves and this is particularly observed in OXA-48 producers (Dautzenberg et al., 2014; Navarro-San Francisco et al., 2013)....
[...]
...Avibactam inhibits both Class A KPC and Class D OXA-48 (Zasowski et al., 2015), while vaborbactam and relebactam inhibits only Class A KPC (Petty et al., 2018; Zhanel et al., 2018) (Table 1)....
[...]
...We also review the newly available antibiotics which have potential in the future treatment of CRE infections: ceftazidime/avibactam, which is active against KPC and OXA-48 producers; meropenem/vaborbactam, which is active against KPC producers; plazomicin, which is a next-generation aminoglycoside with in vitro activity against CRE; and eravacycline, which is a tetracycline class antibacterial with in vitro activity against CRE....
[...]
154 citations
138 citations
136 citations
References
2,189 citations
"The β-Lactams Strike Back: Ceftazid..." refers background or methods in this paper
...” Gram-negative resistance is at the forefront of the discussion, with the Centers for Disease Control and Prevention’s list of top antibiotic resistance threats dominated by gram-negative organisms.(1) This includes the major gram-negative nosocomial pathogens such as multidrug-resistant (MDR) Acinetobacter species and Pseudomonas aeruginosa, extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae, and carbapenem-resistant Enterobacteriaceae (CRE)....
[...]
...According to the Centers for Disease Control and Prevention, CRE are the most urgent unmet medical need that can potentially be addressed by ceftazidime-avibactam.(1) Through potential improvements in clinical efficacy and spared use of more toxic treatment alternatives, such as polymyxin-containing regimens, ceftazidime-avibactam may have a profound impact on the outcomes of patients with CRE infections....
[...]
1,225 citations
649 citations
415 citations